# OnCo record myd88-l265p (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/myd88-l265p/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "myd88-l265p" ;
  schema:name "MYD88 L265P and CXCR4 mutations"@en ;
  schema:alternateName "MYD88"@en, "MYD88 L265P"@en, "MYD88 mutation"@en, "MYD88-mutated"@en, "MYD88 wild-type"@en, "MYD88wt"@en, "CXCR4 mutation"@en, "CXCR4 S338X"@en, "CXCR4 WHIM-like mutation"@en, "MYD88/CXCR4 genotype"@en, "CD79B mutation"@en, "MCD subtype DLBCL"@en, "cluster 5 DLBCL"@en ;
  schema:description "One letter change in MYD88 (L265P) keeps a B-cell survival signal permanently on; it is found in more than nine in ten Waldenström's macroglobulinaemia, most primary CNS and testicular lymphomas and a poor-risk group of DLBCL, and it predicts that BTK inhibitors will work, while a second mutation in CXCR4 predicts that they will work more slowly."@en ;
  schema:url <https://onco.cc/terms/myd88-l265p/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/MYD88> ;
  schema:citation <https://en.wikipedia.org/wiki/MYD88> ;
  onco:related <https://onco.cc/targets/cxcr4/>, <https://onco.cc/targets/btk/>, <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/drugs/zanubrutinib/>, <https://onco.cc/drugs/acalabrutinib/>, <https://onco.cc/drugs/bendamustine/>, <https://onco.cc/terms/cell-of-origin/>, <https://onco.cc/terms/ngs/>, <https://onco.cc/terms/ctdna/> ;
  onco:cancers <https://onco.cc/cancers/waldenstrom/>, <https://onco.cc/cancers/primary-cns-lymphoma/>, <https://onco.cc/cancers/marginal-zone-lymphoma/>, <https://onco.cc/cancers/dlbcl/> .